CO2024009334A2 - Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina - Google Patents

Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina

Info

Publication number
CO2024009334A2
CO2024009334A2 CONC2024/0009334A CO2024009334A CO2024009334A2 CO 2024009334 A2 CO2024009334 A2 CO 2024009334A2 CO 2024009334 A CO2024009334 A CO 2024009334A CO 2024009334 A2 CO2024009334 A2 CO 2024009334A2
Authority
CO
Colombia
Prior art keywords
oxazepine
pyrido
bcl
pyrrolo
tetrahydro
Prior art date
Application number
CONC2024/0009334A
Other languages
English (en)
Spanish (es)
Inventor
George A Doherty
Vikram Bhat
Patrick Brady
Yujia Dai
Jianchun Gong
Andrew S Judd
Andrew J Souers
Yiyun Yu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CO2024009334A2 publication Critical patent/CO2024009334A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2024/0009334A 2022-01-21 2024-07-15 Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina CO2024009334A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Publications (1)

Publication Number Publication Date
CO2024009334A2 true CO2024009334A2 (es) 2024-07-18

Family

ID=85382827

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0009334A CO2024009334A2 (es) 2022-01-21 2024-07-15 Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina

Country Status (13)

Country Link
US (3) US11964990B2 (cg-RX-API-DMAC7.html)
EP (1) EP4466273A1 (cg-RX-API-DMAC7.html)
JP (2) JP7714811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240136972A (cg-RX-API-DMAC7.html)
CN (1) CN119053610A (cg-RX-API-DMAC7.html)
AR (1) AR128310A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023210279A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009334A2 (cg-RX-API-DMAC7.html)
IL (1) IL312709A (cg-RX-API-DMAC7.html)
MX (1) MX2024008840A (cg-RX-API-DMAC7.html)
TW (1) TW202340210A (cg-RX-API-DMAC7.html)
WO (1) WO2023141536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022010410A (es) 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Also Published As

Publication number Publication date
AU2023210279A1 (en) 2024-05-23
JP2025504382A (ja) 2025-02-12
IL312709A (en) 2024-07-01
CA3242074A1 (en) 2023-07-27
AR128310A1 (es) 2024-04-17
TW202340210A (zh) 2023-10-16
US20230234971A1 (en) 2023-07-27
KR20240136972A (ko) 2024-09-19
US20250066388A1 (en) 2025-02-27
MX2024008840A (es) 2024-07-25
EP4466273A1 (en) 2024-11-27
JP7714811B2 (ja) 2025-07-29
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
US20260028356A1 (en) 2026-01-29
CN119053610A (zh) 2024-11-29
JP2025160251A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
CU20210015A7 (es) COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
MX2020011250A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CO2022008091A2 (es) Inhibidores de kras g12c
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
DOP2019000091A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CY1120179T1 (el) Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
CO2018011064A2 (es) Inhibidores de bromodominios
DOP2005000064A (es) Nuevos compuestos
PY2005283A (es) Inhibidores de cdk2
CR20230485A (es) Derivados de fósforo como nuevos inhibidores de sos1
DOP2002000422A (es) Agentes antibacterianos.
MX385838B (es) Derivados de 3-tetrazolil-bencen-1,2-disulfonamida como inhibidores de metalo-beta-lactamasa.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
MX2019009351A (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cancer.
PY2000386A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
CO2024014618A2 (es) Inhibidores de malt-1 de tiazolo[5,4-b]piridina
MX2024008840A (es) Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2
CO2024006398A2 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
DOP2002000386A (es) Agentes antibacterianos
ECSP088968A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY39570A (es) Inhibidores de la tirosina quinasa de bruton de pirazol bicíclico